NCT05182567 - GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

January 10, 2023

Study Completion Date

December 31, 2023

Conditions

COVID-19Healthy

Interventions

DRUG

GLS-5310 (Group 1)

GLS-5310 DNA plasmid vaccine

DRUG

GLS-5310 (Group 2)

GLS-5310 DNA plasmid vaccine

DRUG

GLS-5310 (Group 3)

GLS-5310 DNA plasmid vaccine

DRUG

GLS-5310 (Group 4)

GLS-5310 DNA plasmid vaccine

Trial Locations (3)

Meridian Clinical Research, Rockville

Meridian Clinical Research, Lincoln

Clinical Research Puerto Rico, San Juan